Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SRPT

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Class Action Details - The class period for the lawsuit is from June 22, 2023, to June 24, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to contact the firm for potential lead plaintiff appointment, although this is not required for recovery [1][4]. Allegations Against Sarepta Therapeutics - The complaint alleges that Sarepta Therapeutics made materially false and/or misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy [3]. - Specific allegations include: - ELEVIDYS poses significant safety risks to patients [3]. - The trial protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Next Steps for Shareholders - Shareholders are advised to register for the class action by August 25, 2025, to participate in the case [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software [4]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].